$IMNP Prospectus Supplement Summary

The following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus supplement. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference, which are described under “Incorporation of Certain Information by Reference” in this prospectus supplement and under “Where You Can Find More Information” and “Incorporation of Certain Information by Reference” and in the accompanying prospectus. You should also carefully consider the matters discussed in the section entitled “Risk Factors” in this prospectus supplement, in the accompanying prospectus and in other periodic reports incorporated herein by reference.

Overview

Immune Pharmaceuticals Inc., together with its subsidiaries (“Immune” or the “Company”), is a clinical stage biopharmaceutical company specializing in the development and commercialization of novel targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company focuses on a precision medicine approach to treatment of diseases by incorporating methods for better patient selection in its clinical trials and the potential for development of companion diagnostics. The Company’s Immuno-inflammation product pipeline includes: bertilimumab, a clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation, a portfolio of clinical-stage immune oncology products and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis.

We focus on a precision medicine approach to treatment of diseases by incorporating methods for better patient selection in its clinical trials and the potential for development of companion diagnostics. Our Immuno-inflammation product pipeline includes: bertilimumab, a clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation, a portfolio of clinical-stage immune oncology products and nanocyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis.

Our current product portfolio is summarized in the table below:

Product(s)/
Product Candidate(s)
Primary Indication(s) Status Commercialization Rights
BERTILIMUMAB Bullous Pemphigoid Phase II Immune (Worldwide)
IBD (Crohn's and ulcerative colitis) Phase II Immune (Worldwide)
Atopic Dermatitis Planned Phase I/II Immune (Worldwide)
NASH Planned Phase I/II Immune (Worldwide)
NANOCYCLO (cyclosporin-A) Atopic Dermatitis, Psoriasis Preclinical Immune (Worldwide)
IMMUNO-ONCOLOGY
Crolibulin Solid Tumors Phase II Immune (Worldwide)
Azixa Glioblastoma multiforme Phase II Immune (Worldwide)
NanomAbs Solid Tumors Preclinical Immune (Worldwide)
Bispecific Antibodies Oncology Preclinical Immune (Worldwide)
Ceplene Acute Myeloid Leukemia (in combination with IL-2) Phase III/ (owned in the EU and RoW by Meda AB) Immune (Americas, Israel), Meda (EU, RoW)
OTHER/ PAIN
AmiKet Neuropathic Pain Phase III (Ready) Immune (Worldwide)
LidoPAIN Pain Phase II Immune (Worldwide)
S-1